Keros Therapeutics, Inc.
KROS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001664710
In the last 90 days, Keros Therapeutics, Inc. insiders filed 2 open-market purchases and 4 sales; 132 institutions reported holding it in 13F filings for Q2 2026, worth $198.6M in total; no superinvestor holds it.
13F holders, Q3 2023
Institutional positions in Keros Therapeutics, Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 107
- −16 vs. Q2 2023
- Shares held
- 22.9M
- +492.3K (+2.2%) vs. Q2 2023
- Total value
- $730.6M
- −$170.4M (−18.9%) vs. Q2 2023
- New holders
- 4
- 48 more added
- Sold out
- 20
- 29 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting KROS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 132 | $198.6M |
| Q1 2026 | 151 | $205.6M |
| Q4 2025 | 166 | $408.4M |
| Q3 2025 | 155 | $558.0M |
| Q2 2025 | 139 | $479.6M |
| Q1 2025 | 156 | $428.6M |
| Q4 2024 | 161 | $582.1M |
| Q3 2024 | 164 | $2.03B |
| Q2 2024 | 152 | $1.44B |
| Q1 2024 | 147 | $2.08B |
| Q4 2023 | 121 | $1.02B |
| Q3 2023 | 107 | $730.6M |
| Q2 2023 | 123 | $901.0M |
| Q1 2023 | 129 | $937.0M |
| Q4 2022 | 126 | $948.2M |
| Q3 2022 | 113 | $680.1M |
| Q2 2022 | 104 | $479.7M |
| Q1 2022 | 106 | $893.0M |
| Q4 2021 | 99 | $944.5M |
| Q3 2021 | 89 | $545.4M |
| Q2 2021 | 80 | $599.7M |
| Q1 2021 | 83 | $887.0M |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Keros Therapeutics, Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Price T Rowe Associates Inc | 1,267,232 | $40.4M | 0.01% | −3,129−0.2% | Reduced |
| Braidwell LP | 1,357,309 | $43.3M | 1.37% | +213,444+18.7% | Added |
| Vanguard Group Inc | 1,406,431 | $44.8M | 0.00% | +222,652+18.8% | Added |
| OrbiMed Advisors LLC | 1,514,734 | $48.3M | 1.12% | 00.0% | Unchanged |
| Alkeon Capital Management LLC | 1,676,522 | $53.4M | 0.34% | 00.0% | Unchanged |
| BlackRock Inc. | 1,867,349 | $59.5M | 0.00% | +122,952+7.0% | Added |
| FMR LLC | 3,604,928 | $114.9M | 0.01% | −454,113−11.2% | Reduced |
| Clal Insurance Enterprises Holdings Ltd | 0 | $0 | 0.00% | −299,000−100.0% | Sold out |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −62,650−100.0% | Sold out |
| Kennedy Capital Management, Inc. | 0 | $0 | 0.00% | −58,119−100.0% | Sold out |
| Integral Health Asset Management, LLC | 0 | $0 | 0.00% | −52,000−100.0% | Sold out |
| PFM Health Sciences, LP | 0 | $0 | 0.00% | −20,350−100.0% | Sold out |
| AQR Capital Management LLC | 0 | $0 | 0.00% | −11,441−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −8,770−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −8,708−100.0% | Sold out |
| Campbell & CO Investment Adviser LLC | 0 | $0 | 0.00% | −7,745−100.0% | Sold out |
| J. Goldman & Co LP | 0 | $0 | 0.00% | −7,677−100.0% | Sold out |
| Jump Financial, LLC | 0 | $0 | 0.00% | −7,283−100.0% | Sold out |
| STRS Ohio | 0 | $0 | 0.00% | −5,700−100.0% | Sold out |
| Arizona State Retirement System | 0 | $0 | 0.00% | −5,611−100.0% | Sold out |
| Teacher Retirement System of Texas | 0 | $0 | 0.00% | −5,409−100.0% | Sold out |
| Virtus Investment Advisers, Inc. | 0 | $0 | 0.00% | −2,953−100.0% | Sold out |
| Aquatic Capital Management LLC | 0 | $0 | 0.00% | −2,200−100.0% | Sold out |
| Meitav Dash Investments Ltd | 0 | $0 | 0.00% | −1,597−100.0% | Sold out |
| Virtus Fund Advisers, LLC | 0 | $0 | 0.00% | −535−100.0% | Sold out |
| US Bancorp | 0 | $0 | 0.00% | −55−100.0% | Sold out |
| Quadrant Capital Group LLC | 0 | $0 | 0.00% | −6−100.0% | Sold out |